Hexima Investor Updates
It is our pleasure to report on an exciting year at Hexima, during which we progressed our lead drug candidate, HXP124, into first-in-human clinical trials. This is a pivotal step in the development of HXP124 as a safe and effective treatment for fungal nail...read more
Hexima Limited is pleased to welcome Mr Justin Yap as a Non-Executive Director, effective 17th July 2018. Mr Yap is an Executive Director of CathRx Limited, an Australian medical device company commercialising novel cardiac electrophysiology catheters for the...read more
Shares in Hexima Limited are not traded on the ASX. The last off-market transfer of shares registered by the Company, as at the close of business on 30 June 2018, was at the price of $0.08 per share. Download a copy of this announcement...read more
Hexima’s Annual Financial Report - year ended June 30 2018 (pdf) is now online.
Hexima Limited Interim Financial Report for the 6 Months ended 31 December 2017
Presentations and Results from the 2017 Hexima Limited Annual General Meeting held 21st November 2017